Akoya Biosciences, Inc. (AKYA)
NASDAQ: AKYA · Real-Time Price · USD
1.160
+0.060 (5.45%)
At close: May 12, 2025, 4:00 PM
1.150
-0.010 (-0.86%)
After-hours: May 12, 2025, 6:05 PM EDT
Akoya Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Akoya Biosciences stock have an average target of 2.65, with a low estimate of 1.65 and a high estimate of 5.00. The average target predicts an increase of 128.45% from the current stock price of 1.16.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Akoya Biosciences stock from 7 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $3.5 → $1.8 | Hold | Maintains | $3.5 → $1.8 | +55.17% | Apr 29, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $2.4 → $1.65 | Hold | Maintains | $2.4 → $1.65 | +42.24% | Apr 14, 2025 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $3.5 → $1.8 | Buy → Hold | Downgrades | $3.5 → $1.8 | +55.17% | Mar 25, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $3.5 | Buy | Reiterates | $3.5 | +201.72% | Mar 18, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $4 → $3 | Buy | Reiterates | $4 → $3 | +158.62% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
92.54M
from 81.67M
Increased by 13.30%
Revenue Next Year
105.50M
from 92.54M
Increased by 14.01%
EPS This Year
-0.65
from -1.12
EPS Next Year
-0.50
from -0.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 99.2M | 118.6M | 134.7M | ||
| Avg | 92.5M | 105.5M | 113.1M | ||
| Low | 85.6M | 90.2M | 95.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.5% | 28.1% | 27.7% | ||
| Avg | 13.3% | 14.0% | 7.2% | ||
| Low | 4.8% | -2.6% | -9.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.46 | -0.36 | -0.48 | ||
| Avg | -0.65 | -0.50 | -0.50 | ||
| Low | -0.74 | -0.65 | -0.50 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.